LSM-775 (lysergic acid morpholide, also known as N-morpholinyllysergamide) is a synthetic psychedelic of the lysergamide family, structurally distinguished from LSD by the replacement of the diethyl amide group with a morpholine ring. This substitution places a 6-membered oxygen-containing ring at the amide position of the lysergic acid core, significantly altering the steric and electronic properties of the molecule at the amide binding pocket of 5-HT2A receptors.
LSM-775 is less potent than LSD on a microgram-per-microgram basis, with active doses typically reported in the hundreds of micrograms range. Community reports describe the experience as having a somewhat softer, more dreamy quality compared to LSD, with less pronounced stimulation and a character that users frequently describe as more hypnagogic and less cognitively demanding than LSD at comparable effect intensity. Duration is reported as approximately 8–10 hours, similar to LSD.
LSM-775 attracted attention in research chemical communities as one of the relatively rare non-LSD-prodrug lysergamides — unlike most of the 1-acyl series, it is not believed to convert to LSD but rather to act directly in its own right. This makes its receptor pharmacology and subjective character genuinely distinct from LSD rather than simply being a delivery vehicle for it. Community reports are sparse relative to 1P-LSD or LSD, reflecting its more obscure position in the lysergamide landscape.
As with all lysergamides, testing with Ehrlich reagent (purple/violet) is essential before use, and the standard contraindications — personal or family history of psychosis, lithium or MAOI use, cardiovascular disease — apply fully.
Safety at a Glance
High Risk- Ehrlich reagent: purple/violet confirms indole compound. As LSM-775 is less commonly encountered, adulteration risk f...
- LSM-775 is less potent than LSD — active doses in the community are reported at several hundred micrograms:
- Toxicity: Acute Toxicity No formal toxicological data exist for LSM-775 in humans. Acute toxicity by structural analogy to LSD ...
- Overdose risk: Fatal overdose from LSM-775 alone, at doses within the typical recreational range, is extremely u...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 10 hrsHow It Feels
The experience begins with almost nothing. A slight shift in body awareness, perhaps, a feeling that the air in the room has become fractionally more present. LSM-775 operates at the very threshold of psychoactive effect, and its onset is accordingly delicate, a suggestion rather than a statement.
Physically, the substance is remarkably gentle. There is no significant body load, no nausea, no muscular tension. A mild warmth may settle in the torso, and there can be a subtle increase in skin sensitivity, but these effects hover at the boundary of perception. The body remains comfortable, relaxed, and essentially normal. Walking, eating, and physical activity proceed without any notable alteration.
At peak effect, LSM-775 produces a state that might best be described as enhanced ordinariness. The world does not transform; it simply becomes slightly more interesting. Textures gain a marginal increase in definition. Music acquires a faintly richer emotional resonance. There may be a gentle uplift in mood, a quiet cheerfulness that colors ordinary activities with mild pleasure. Thought patterns shift subtly toward increased openness and association, but there is no psychedelic confusion, no perceptual distortion worthy of the name. If you were not paying careful attention to your own mental state, you might attribute the effects to a good night of sleep or a particularly pleasant afternoon.
The offset arrives without ceremony. After three to four hours the subtle enhancement simply evaporates, leaving no residue, no depletion, no cognitive fog. LSM-775 occupies a curious position in the lysergamide family: potent enough to confirm that it is indeed psychoactive, but so mild that its primary interest is pharmacological rather than experiential. It demonstrates the minimum effective expression of the lysergamide architecture, a whisper from the same molecular family that produces some of the most powerful experiences known to human consciousness.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(27)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Mouth numbing— Mouth numbing is a localized loss of sensation in the tongue, gums, cheeks, and surrounding oral tis...
- Muscle cramp— Muscle cramps are sudden, involuntary, and often painful contractions of muscles that occur as a sid...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
- Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...
Cognitive & Perceptual Effects
Visual(17)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(19)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(3)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(3)
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Perception of self-design— Perception of self-design is the powerful and often paradoxical feeling that one has personally auth...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
LSM-775 acts directly as a partial agonist at serotonin 5-HT2A receptors rather than as a prodrug for LSD. The morpholine ring substitution at the amide position alters binding geometry in the 5-HT2A receptor binding pocket relative to LSD's diethyl amide, which accounts for its reduced potency per microgram and potentially different receptor signaling characteristics. As with all lysergamides, 5-HT2A partial agonism in cortical pyramidal neurons drives the core psychedelic effects through disruption of predictive-coding hierarchies and enhanced thalamocortical glutamate release.
Receptor Targets
- 5-HT2A receptors — primary psychedelic target; partial agonist; morpholine substitution reduces affinity relative to LSD but retains activity
- 5-HT1A receptors — likely partial agonist; may contribute to the reportedly softer, more dreamy character
- 5-HT2C receptors — expected affinity; contributes to anxiogenic potential
- Dopamine D2/D3 receptors — likely moderate affinity; stimulant component
- N-Morpholine receptor profile* — the morpholine oxygen may produce distinct interactions with the receptor binding pocket relative to purely carbon-chain substituents, potentially shifting the signaling bias
Pharmacokinetics
No formal human pharmacokinetic data exist for LSM-775. Based on structural similarity to LSD, absorption is expected to be rapid and efficient via oral or sublingual routes. Onset is community-reported at approximately 45–75 minutes. Peak effects at 2–4 hours. Duration approximately 8–10 hours. Metabolism is likely hepatic with glucuronidation and hydroxylation.
Tolerance
Cross-tolerance with LSD and all serotonergic psychedelics is expected. Functional tolerance develops within 24–48 hours and reverses over 5–7 days.
Detection Methods
Urine Detection
LSM-775 and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for LSM-775 are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
LSM-775 is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for LSM-775. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
LSM-775 (lysergic acid morpholide) was synthesized as part of the systematic exploration of lysergic acid amide derivatives conducted primarily in the mid-20th century by Albert Hofmann and colleagues at Sandoz Laboratories. This research program, which produced LSD itself, explored dozens of amide substitutions on the lysergic acid core to map the structure-activity relationship. LSM-775 was among the less clinically developed analogs, noted for activity but not pursued for pharmaceutical development.
Research Chemical Era
LSM-775 gained modest attention in the research chemical community in the 2010s as users and researchers explored lysergamide diversity. Its distinct receptor pharmacology relative to LSD prodrugs made it of interest to those seeking experiences genuinely different from LSD rather than simply LSD-equivalent.
Legal Status
LSM-775 is not specifically scheduled under international drug conventions but is captured under novel psychoactive substance laws in the UK and many European countries. It may be subject to analog act provisions in the United States. Local legal status should be verified before obtaining or possessing this compound.
Harm Reduction
Testing
Ehrlich reagent: purple/violet confirms indole compound. As LSM-775 is less commonly encountered, adulteration risk from more dangerous compounds is a meaningful concern.
Dosing
LSM-775 is less potent than LSD — active doses in the community are reported at several hundred micrograms:
- Threshold: 75–125 μg
- Light: 125–250 μg
- Common: 250–500 μg
- Strong: 500–750 μg
These ranges are significantly higher than LSD in absolute microgram terms. This is important for harm reduction: tabs or solutions labeled by weight may contain large doses. Community reports specifically note the much higher active dose compared to LSD.
Set and Setting
- Stable emotional state; familiar environment; trip sitter recommended
- The reportedly softer character may make LSM-775 more forgiving than LSD, but dose-dependent adverse effects remain possible
- The dreamy, hypnagogic quality community members report suggests potentially good synergy with comfortable indoor settings and music
Dangerous Combinations
- Lithium — Contraindicated; seizure and cardiac events with lysergamides
- MAOIs — Serotonin syndrome risk
- Tramadol — Seizure risk
- Cannabis — Risk of amplified anxiety
- Stimulants — Cardiovascular and psychological intensity amplification
Emergency Protocol
- Benzodiazepines for acute distress; environment change and grounding techniques
- Emergency services for any physical safety concerns
Toxicity & Safety
Acute Toxicity
No formal toxicological data exist for LSM-775 in humans. Acute toxicity by structural analogy to LSD is expected to be very low. No pharmacological fatalities have been reported. Primary risks are psychological.
Cardiovascular Effects
Sympathomimetic effects consistent with the lysergamide class are expected: mild tachycardia, blood pressure elevation, mydriasis. Individuals with cardiovascular disease should not use this compound.
Psychological Risks
- Acute anxiety and panic — Risk mirrors lysergamide class; dose-dependent
- Psychosis induction — Absolute contraindication with history of schizophrenia or bipolar I disorder
- HPPD — Risk with any serotonergic psychedelic
Contraindications
Personal or family history of psychosis or bipolar disorder; lithium, MAOI, antipsychotic, or tramadol use; cardiovascular disease.
Overdose
No documented pharmacological overdoses. Benzodiazepines for acute psychological distress.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from LSM-775 alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Germany: LSM-775 is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: LSM-775 can be considered a controlled substance as a defined derivative (Alkoxyalkyl) of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
Responsible use (Hallucinogens)
Psychoactive substance index
Research chemical
Hallucinogens
Psychedelic
Lysergamide
LSM-775 (Wikipedia)
LSM-775 (Isomer Design)
The Big & Dandy LSM-775 (Lysergic Acid Morpholide) Thread (Bluelight)
TheDrugClassroom (LSM-775)
Gogerty, J. H., & Dille, J. M. (1957). Pharmacology of d-lysergic acid morpholide (LSM). Journal of Pharmacology and Experimental Therapeutics, 120(3), 340-348. PMID: 13476356
Experience Reports (2)
Tips (5)
Integration is just as important as the experience itself. After using LSM-775, take time to journal, reflect, or discuss the experience. Insights from psychedelic states can be powerful but need conscious effort to apply to daily life.
Do not combine LSM-775 with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
If you experience anxiety or thought loops on LSM-775, change your physical environment: move to a different room, go outside, change the music, or hold something cold. A change of scenery can instantly shift a difficult headspace.
Set and setting are paramount with LSM-775. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
Start with a low dose of LSM-775 if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
See Also
Same Class
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: LSM-775
PubChem compound page for LSM-775 (CID: 199507)
pubchem - LSM-775 - TripSit Factsheet
TripSit factsheet for LSM-775
tripsit - LSM-775 - Wikipedia
Wikipedia article on LSM-775
wikipedia